CAJ | 학술논문

目的观察辛伐他汀和非诺贝特在治疗大鼠非酒精性脂肪肝病(nonalcoholic fatty liver disease,NAFLD)过程中,大鼠血清脂肪甘油三酯脂酶(adipose triglyceride lipase,ATGL)活性和TNF-α水平的变化以及两者间的关系.方法78只雄性SD大鼠随机分为正常对照组(15只)和NAFLD模型组(63只).高脂饲料建立NAFLD大鼠模型,于12周末检测血脂,病理学证实造模成功后,将模型组随机分为4组:NAFLD对照组,辛伐他汀组,非诺贝特组和饮食组.16周末,处死所有动物,检测血清TG、TC、FBG、ALT、AST、BUN、Scr及ATGL和TNF-α水平,计算肝指数及观察肝脏病理变化.结果两药物组血清TNF-α水平分别为290±78,332±89,ATGL酶浓度分别为0.69±0.21,0.63±0.20,而NAFLD模型组TNF-α水平为485±115,ATGL酶浓度为0.43±0.22,两药物组血清TNF-α水平较模型组明显下降(P<0.05),而ATGL酶活性显著升高(P<0.01),且肝组织病理明显改善;饮食组血清TNF-α水平及ATGL酶浓度分别为432±102,0.52±0.19,两药物组血清ATGL和TNF-α水平较饮食组恢复显著(均P<0.05);NAFLD大鼠血清TNF-α与ATGL呈高度负相关(r=0.948, P<0.01).结论 NAFLD大鼠血清ATGL酶活性与TNF-α高度相关;辛伐他汀和非诺贝特可通过降低TNF-α水平而增强ATGL酶活性有效治疗大鼠NAFLD.
목적관찰신벌타정화비낙패특재치료대서비주정성지방간병(nonalcoholic fatty liver disease,NAFLD)과정중,대서혈청지방감유삼지지매(adipose triglyceride lipase,ATGL)활성화TNF-α수평적변화이급량자간적관계.방법78지웅성SD대서수궤분위정상대조조(15지)화NAFLD모형조(63지).고지사료건립NAFLD대서모형,우12주말검측혈지,병이학증실조모성공후,장모형조수궤분위4조:NAFLD대조조,신벌타정조,비낙패특조화음식조.16주말,처사소유동물,검측혈청TG、TC、FBG、ALT、AST、BUN、Scr급ATGL화TNF-α수평,계산간지수급관찰간장병리변화.결과량약물조혈청TNF-α수평분별위290±78,332±89,ATGL매농도분별위0.69±0.21,0.63±0.20,이NAFLD모형조TNF-α수평위485±115,ATGL매농도위0.43±0.22,량약물조혈청TNF-α수평교모형조명현하강(P<0.05),이ATGL매활성현저승고(P<0.01),차간조직병리명현개선;음식조혈청TNF-α수평급ATGL매농도분별위432±102,0.52±0.19,량약물조혈청ATGL화TNF-α수평교음식조회복현저(균P<0.05);NAFLD대서혈청TNF-α여ATGL정고도부상관(r=0.948, P<0.01).결론 NAFLD대서혈청ATGL매활성여TNF-α고도상관;신벌타정화비낙패특가통과강저TNF-α수평이증강ATGL매활성유효치료대서NAFLD.
Objective To observe the effect of simvastatine and fenofibrate on adipose serum triglyceride lipase (ATGL) and TNF-αlevels in rats with non-alcoholic fatty acid liver disease (NAFLD). Methods Seventy-eight male SD rats were randomly divided into normal group(n=15) and NAFLD model group(n=63). Rats in normal control group were fed with normal diet and those in NAFLD model group were fed with high-fat diet. Their serum TG and TC levels were measured at the end of 12 weeks. After a rat NAFLD model was established, the rats in NAFLD model group were randomly divided into NAFLD control group, simvastatine treatment group, fenofibrate treatment group, and diet group. The animals were killed and their serum TG, TC, ALT, AST, BUN, Scr, fasting blood glucose (FBG), TNF-αand ATGL levels were measured at the end 16 weeks, their liver index was counted, and their liver pathologic changes were observed. Results The serum TNF-α and ATGL levels were 290±78 and 332±89, 0.69±0.21 and 0.63±0.20, 485±115 and 0.43±0.22, respectively, in simvastatine treatment group, fenofibrate treatment group and NAFLD model group (P < 0.05, P < 0.01). The liver pathological lesions were significantly improved in simvastatine treatment group and fenofibrate treatment group. The serum ATGL and TNF-αlevels were significantly higher in diet group than in NAFLD control group(0.52±0.19 vs 0.43±0.22, P<0.05). The serum TNF-αlevel was negatively related with the serum ATGL level(r=0.948, P<0.01). Conclusion Serum ATGL activity is closely correlated with serum TNF-αlevel in rats with NAFLD. Simvastatine and fenofibrate can increase the ATGL activity by decreasing the serum TNF-αlevel, thus effectively alleviating NAFLD.